Amgen is significantly boosting its investment in biomanufacturing, committing an additional $300 million to its facility in Juncos, Puerto Rico, following a previous $650 million expansion announced last year.
This latest funding is part of a broader strategy by Amgen, which has dedicated over $2 billion to U.S. manufacturing in the past year. This includes substantial investments in other locations, such as $900 million in New Albany, Ohio, and $600 million for a science and innovation center in Thousand Oaks, California. The Juncos facility, which has evolved into a major biomanufacturing site over its 34-year history, is now recognized as one of the most advanced in the world, producing biologics for over 60 countries.
Amgen's CEO, Robert Bradway, emphasized the company's commitment to American manufacturing and the importance of the Puerto Rico site in ensuring patient access to essential medicines. The expansion is expected to generate hundreds of construction jobs initially and enhance existing advanced-manufacturing roles, contributing to workforce development in the region.
Puerto Rico's government officials have praised the investment, highlighting the island's long-standing reputation in the biopharmaceutical sector and its skilled workforce. The $300 million commitment, along with the earlier investment, signals confidence in Puerto Rico's capabilities and aims to solidify its position as a leading destination for advanced manufacturing in the U.S.